Identifying genetic markers in lung cancer
Detection of Genetic Markers of Lung Cancer Initiation and Progression
This study is trying to find out which genetic changes are linked to lung cancer to help understand how it develops and progresses.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Pittsburgh Academic / other |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Trial ID | NCT00280202 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify the genetic and immunologic changes associated with the development and progression of bronchogenic lung cancer. It focuses on the multistage theory of carcinogenesis, examining how genetic alterations due to carcinogen exposure lead to malignant transformation. The study involves biopsies of the bronchial tree and analysis of chromosomal abnormalities, as well as the evaluation of tumor DNA mutations and cytokine levels. By utilizing advanced molecular biology techniques, the research seeks to uncover specific genomic changes that contribute to lung cancer.
Who should consider this trial
Good fit: Ideal candidates include individuals with histologically confirmed lung cancer or suspicious lung lesions who are scheduled for biopsy or surgical resection.
Not a fit: Patients without a confirmed diagnosis of lung cancer or those not undergoing biopsy or surgical intervention may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of lung cancer genetics, leading to improved diagnostic and therapeutic strategies.
How similar studies have performed: Other studies have shown success in identifying genetic markers in various cancers, suggesting that this approach may yield valuable insights in lung cancer as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologic confirmation of lung cancer, lung metastases from a primary site other than lung, mesothelioma or a radiographic lesion highly suspicious for malignancy * Written informed consent. * To be scheduled for a biopsy or surgical resection or have already had a biopsy and/or surgical removal of a lung mass Exclusion Criteria: None
Where this trial is running
Pittsburgh, Pennsylvania
- Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Arjun Pennathur, MD — Professor (with tenure) of Cardiothoracic Surgery
- Study coordinator: Arjun Pennathur, MD
- Email: pennathura@upmc.edu
- Phone: 412-647-7555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.